Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery

T-cell leukemias and lymphomas (TCLs) form a heterogeneous group of rare and often aggressive malignancies. Due to the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multi-omics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multi-omics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations, and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype-specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL.

Princess Margaret Cancer Centre
Universitätsklinikum Leipzig
Hospital District of Helsinki and Uusimaa
Université Claude Bernard Lyon 1
Helsinki University Hospital
Oslo University Hospital
Universitätsklinikum Köln
Comprehensive Cancer Center Vienna
Universität zu Köln
Medizinische Universität Wien - AKH
University of Toronto
University of Helsinki
Vector Institute
Hospices Civils de Lyon, Pierre-Bénite cedex, France
Harmonic Discovery
Universität Salzburg